Alignment Healthcare, Inc. (NASDAQ: ALHC), a tech-enabled Medicare
Advantage company, today reported financial results for its third
quarter ended Sept. 30, 2022.
“Alignment Healthcare’s solid performance in the third quarter
is a testament to the repeatability and scalability of our
operating model,” said John Kao, founder and CEO. “The quarter
shows how strategic long-term investments in our people and our
technology allow us to effectively deliver durable financial
results across the markets we serve.”
“Key to this success is Alignment’s proprietary data platform
AVA® and the insights it provides across our business to drive
value and innovation year after year, as evidenced by our 2023 star
ratings,” Kao added. “Achieving 5 out of 5 stars in North Carolina
in our first year and maintaining a notable 4 out of 5 stars
for our HMO plan in California for the sixth consecutive year puts
approximately 95% of our members in plans rated 4 stars or greater,
at a time when the number of plans nationwide achieving 4- and
5-star ratings have dropped by double-digit percentages over the
last year. This quarter’s results have added significant momentum
to an already impressive first half of the year and drive
confidence in our team’s ability to achieve our full-year financial
targets.”
Third Quarter 2022 Financial HighlightsAll
comparisons, unless otherwise noted, are to the three months ended
Sept. 30, 2021.
- Health plan membership at the end of the quarter was
approximately 98,000, up 14.0% year over year
- Total revenue was $360.3 million, up 22.8% year over year
- Health plan premium revenue of $345.4 million represented 23.9%
growth year over year
- Adjusted gross profit was $49.5 million and loss from
operations was ($33.4) million
- Adjusted gross profit excludes depreciation and amortization of
$4.5 million and selling, general, and administrative expenses of
$76.5 million (which includes $16.8 million of equity-based
compensation). Adjusted gross profit also excludes an additional
$1.9 million of equity-based compensation recorded within
medical expenses
- Medical benefits ratio based on adjusted gross profit was
86.3%
- Adjusted EBITDA was ($9.5) million and net loss was ($40.2)
million
- As of Sept. 30, 2022, total cash was $567.4 million, and debt
was $165.0 million (excluding unamortized debt issuance costs)
- Total cash includes an early payment of approximately $117
million from the Centers for Medicare & Medicaid Services,
reflected in an increase to deferred premium revenue
Adjusted Gross Profit is reconciled as follows:
|
|
Three Months EndedSeptember 30, |
|
Nine Months EndedSeptember 30, |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
(dollars in thousands) |
|
|
|
|
|
|
|
|
Loss from operations |
|
$ |
(33,410 |
) |
|
$ |
(41,450 |
) |
|
$ |
(76,533 |
) |
|
$ |
(134,606 |
) |
Add back: |
|
|
|
|
|
|
|
|
Equity-based compensation (medical expenses) |
|
|
1,912 |
|
|
|
2,435 |
|
|
|
6,751 |
|
|
|
11,458 |
|
Depreciation (medical expenses) |
|
|
57 |
|
|
|
53 |
|
|
|
149 |
|
|
|
159 |
|
Depreciation and amortization |
|
|
4,456 |
|
|
|
4,080 |
|
|
|
12,586 |
|
|
|
11,725 |
|
Selling, general, and administrative expenses |
|
|
76,452 |
|
|
|
76,846 |
|
|
|
212,418 |
|
|
|
212,910 |
|
Total add back |
|
|
82,877 |
|
|
|
83,414 |
|
|
|
231,904 |
|
|
|
236,252 |
|
Adjusted gross profit |
|
$ |
49,467 |
|
|
$ |
41,964 |
|
|
$ |
155,371 |
|
|
$ |
101,646 |
|
Adjusted gross profit % |
|
|
13.7 |
% |
|
|
14.3 |
% |
|
|
14.5 |
% |
|
|
11.7 |
% |
Medical benefit ratio |
|
|
86.3 |
% |
|
|
85.7 |
% |
|
|
85.5 |
% |
|
|
88.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA is reconciled as follows:
|
|
Three Months EndedSeptember 30, |
|
Nine Months EndedSeptember 30, |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
(dollars in thousands) |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(40,247 |
) |
|
$ |
(45,816 |
) |
|
$ |
(92,644 |
) |
|
$ |
(147,452 |
) |
Add back: |
|
|
|
|
|
|
|
|
Interest expense |
|
|
4,605 |
|
|
|
4,414 |
|
|
|
13,496 |
|
|
|
12,991 |
|
Depreciation and amortization |
|
|
4,513 |
|
|
|
4,133 |
|
|
|
12,735 |
|
|
|
11,884 |
|
Income taxes |
|
|
167 |
|
|
|
— |
|
|
|
167 |
|
|
|
— |
|
EBITDA |
|
|
(30,962 |
) |
|
|
(37,269 |
) |
|
|
(66,246 |
) |
|
|
(122,577 |
) |
Equity-based compensation(1) |
|
|
18,687 |
|
|
|
30,511 |
|
|
|
58,833 |
|
|
|
93,185 |
|
Reorganization and transaction-related expenses(2) |
|
|
579 |
|
|
|
457 |
|
|
|
579 |
|
|
|
4,058 |
|
Acquisition expenses(3) |
|
|
7 |
|
|
|
789 |
|
|
|
1,066 |
|
|
|
1,090 |
|
Loss on sublease(4) |
|
|
— |
|
|
|
— |
|
|
|
509 |
|
|
|
— |
|
Loss on extinguishment of debt |
|
|
2,196 |
|
|
|
— |
|
|
|
2,196 |
|
|
|
— |
|
Adjusted EBITDA |
|
$ |
(9,493 |
) |
|
$ |
(5,512 |
) |
|
$ |
(3,063 |
) |
|
$ |
(24,244 |
) |
(1) |
2022 represents equity-based compensation related to grants made in
the current year, as well as equity-based compensation related to
the timing of the IPO, which includes previously issued stock
appreciation rights liability awards, modifications related to
transaction vesting units, and grants made in conjunction with the
IPO. 2021 represents equity-based compensation related to the
timing of the IPO as previously discussed. Equity-based
compensation expense for the nine months ended September 30, 2021
includes $11.4 million related to the cash settlement of pre-IPO
stock appreciation rights. |
(2) |
Represents legal, professional,
accounting and other advisory fees related to our pre-IPO corporate
reorganization and the IPO that are considered non-recurring and
non-capitalizable. |
(3) |
Represents acquisition-related
fees, such as legal and advisory fees, that are
non-capitalizable. |
(4) |
Represents loss related to right
of use (“ROU”) assets that were subleased in the second quarter of
2022. |
|
|
Outlook for Fourth Quarter and Fiscal Year
2022
|
|
Three Months EndingDecember 31,
2022 |
|
Twelve Months EndingDecember 31, 2022 |
$ Millions |
|
Low |
|
High |
|
Low |
|
High |
Health Plan Membership |
|
98,000 |
|
99,000 |
|
98,000 |
|
99,000 |
Revenue |
|
$338 |
|
$343 |
|
$1,410 |
|
$1,415 |
Adjusted Gross Profit1 |
|
$34 |
|
$37 |
|
$189 |
|
$192 |
Adjusted EBITDA2 |
|
($30) |
|
($27) |
|
($33) |
|
($30) |
_______________________
- Adjusted gross profit is a non-GAAP financial measure that is
presented as supplemental disclosure, that we define as loss from
operations before depreciation and amortization, clinical
equity-based compensation expense, and selling, general, and
administrative expenses. We cannot reconcile our estimated ranges
for adjusted gross profit to loss from operations, the most
directly comparable GAAP measure, and cannot provide estimated
ranges for loss from operations, without unreasonable efforts
because of the uncertainty around certain items that may impact
loss from operations, including equity-based compensation expense
and depreciation and amortization, that are not within our control
or cannot be reasonably predicted.
- Adjusted EBITDA is a non-GAAP financial measure that is
presented as supplemental disclosure, that we define as net loss
before interest expense, income taxes, depreciation and
amortization expense, reorganization and transaction-related
expenses, equity-based compensation expense, loss on sublease and
loss on extinguishment of debt. We cannot reconcile our estimated
ranges for Adjusted EBITDA to net loss, the most directly
comparable GAAP measure, and cannot provide estimated ranges for
net loss, without unreasonable efforts because of the uncertainty
around certain items that may impact net loss, including
equity-based compensation expense and depreciation and
amortization, that are not within our control or cannot be
reasonably predicted.
Conference Call DetailsThe company will host a
conference call at 5:30 p.m. EDT today to discuss these results and
management’s outlook for future financial and operational
performance. Participants can pre-register for or join the webcast
at the start of the conference call by navigating to
https://edge.media-server.com/mmc/p/bp29iep6. A live audio webcast
will be available online at https://ir.alignmenthealth.com/. A
replay of the call will be available via webcast for on-demand
listening shortly after the completion of the call, at the same web
links, and will remain available for approximately 12 months.
About Alignment HealthAlignment Health is
championing a new path in senior care that empowers members to age
well and live their most vibrant lives. A consumer brand name of
Alignment Healthcare (NASDAQ: ALHC), Alignment Health is a
tech-enabled Medicare Advantage company that offers more than 40
benefits-rich, value-driven plans that serve 38 counties across
four states. The company partners with nationally recognized and
trusted local providers to deliver coordinated care, powered by its
customized care model, 24/7 concierge care team and purpose-built
technology, AVA®. Based in California, the company’s
mission-focused team makes high-quality, low-cost care a reality
for members every day. As it expands its offerings and grows its
national footprint, Alignment upholds its core values of leading
with a serving heart and putting the senior first. For more
information, visit www.alignmenthealth.com.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
and the Private Securities Litigation Reform Act of 1995, as
amended. These forward-looking statements include statements
regarding our future growth and our financial outlook for the
fourth quarter ending December 31, 2022, and year ending December
31, 2022. Forward-looking statements are subject to risks and
uncertainties and are based on assumptions that may prove to be
inaccurate, which could cause actual results to differ materially
from those expected or implied by the forward-looking statements.
Actual results may differ materially from the results predicted,
and reported results should not be considered as an indication of
future performance. Important risks and uncertainties that could
cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements
include, among others, the following: our ability to attract new
members and enter new markets, including the need for certain
governmental approvals; our ability to maintain a high rating for
our plans on the Five Star Quality Rating System; risks associated
with being a government contractor; changes in laws and regulations
applicable to our business model; risks related to our
indebtedness, including the potential for rising interest rates;
changes in market or industry conditions and receptivity to our
technology and services; results of litigation or a security
incident; the impact of shortages of qualified personnel and
related increases in our labor costs; and the impact of COVID-19 on
our business and results of operation. For a detailed discussion of
the risk factors that could affect our actual results, please refer
to the risk factors identified in our Annual Report on Form 10-K
for the year ended December 31, 2021, and the other periodic
reports we file with the SEC. All information provided in this
release and in the attachments is as of the date hereof, and we
undertake no duty to update or revise this information unless
required by law.
|
Condensed Consolidated Balance Sheets(in
thousands, except par value and share amounts)(Unaudited) |
|
|
|
September 30, 2022 |
|
December 31, 2021 |
Assets |
|
|
|
|
Current Assets: |
|
|
|
|
Cash |
|
$ |
567,446 |
|
|
$ |
466,600 |
|
Accounts receivable (less allowance for credit losses of $217 at
September 30, 2022 and $111 at December 31, 2021,
respectively) |
|
|
88,220 |
|
|
|
58,512 |
|
Prepaid expenses and other current assets |
|
|
36,493 |
|
|
|
27,747 |
|
Total current assets |
|
|
692,159 |
|
|
|
552,859 |
|
Property and equipment, net |
|
|
35,577 |
|
|
|
30,358 |
|
Right of use asset, net |
|
|
6,085 |
|
|
|
7,853 |
|
Goodwill and intangible assets, net |
|
|
37,618 |
|
|
|
35,116 |
|
Other assets |
|
|
6,104 |
|
|
|
4,709 |
|
Total assets |
|
$ |
777,543 |
|
|
$ |
630,895 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
Current Liabilities: |
|
|
|
|
Medical expenses payable |
|
$ |
171,395 |
|
|
$ |
125,886 |
|
Accounts payable and accrued expenses |
|
|
20,691 |
|
|
|
16,962 |
|
Deferred premium revenue |
|
|
116,767 |
|
|
|
469 |
|
Accrued compensation |
|
|
31,411 |
|
|
|
23,928 |
|
Total current liabilities |
|
|
340,264 |
|
|
|
167,245 |
|
Long-term debt, net of debt issuance costs |
|
|
160,677 |
|
|
|
150,620 |
|
Long-term portion of lease liabilities |
|
|
4,458 |
|
|
|
6,975 |
|
Total liabilities |
|
|
505,399 |
|
|
|
324,840 |
|
|
|
|
|
|
Stockholders' Equity: |
|
|
|
|
Preferred stock, $.001 par value; 100,000,000 and 0 shares
authorized as of September 30, 2022 and December 31, 2021,
respectively; no shares issued and outstanding as of September 30,
2022 and December 31, 2021 |
|
|
— |
|
|
|
— |
|
Common stock, $.001 par value; 1,000,000,000 shares authorized as
of September 30, 2022 and December 31, 2021; 187,263,976 and
187,193,613 shares issued and outstanding as of September 30, 2022
and December 31, 2021, respectively |
|
|
187 |
|
|
|
187 |
|
Additional paid-in capital |
|
|
947,295 |
|
|
|
888,547 |
|
Accumulated deficit |
|
|
(675,338 |
) |
|
|
(582,694 |
) |
Total Alignment Healthcare, Inc. stockholders' equity |
|
|
272,144 |
|
|
|
306,040 |
|
Noncontrolling interest |
|
|
— |
|
|
|
15 |
|
Total stockholders' equity |
|
|
272,144 |
|
|
|
306,055 |
|
Total liabilities and stockholders' equity |
|
$ |
777,543 |
|
|
$ |
630,895 |
|
Condensed Consolidated Statements of Operations(in
thousands, except per share amounts)(Unaudited) |
|
|
|
Three Months EndedSeptember 30, |
|
Nine Months EndedSeptember 30, |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Revenues: |
|
|
|
|
|
|
|
|
Earned premiums |
|
$ |
359,978 |
|
|
$ |
293,275 |
|
|
$ |
1,071,450 |
|
|
$ |
869,014 |
|
Other |
|
|
370 |
|
|
|
191 |
|
|
|
898 |
|
|
|
485 |
|
Total revenues |
|
|
360,348 |
|
|
|
293,466 |
|
|
|
1,072,348 |
|
|
|
869,499 |
|
Expenses: |
|
|
|
|
|
|
|
|
Medical expenses |
|
|
312,850 |
|
|
|
253,990 |
|
|
|
923,877 |
|
|
|
779,470 |
|
Selling, general, and administrative expenses |
|
|
76,452 |
|
|
|
76,846 |
|
|
|
212,418 |
|
|
|
212,910 |
|
Depreciation and amortization |
|
|
4,456 |
|
|
|
4,080 |
|
|
|
12,586 |
|
|
|
11,725 |
|
Total expenses |
|
|
393,758 |
|
|
|
334,916 |
|
|
|
1,148,881 |
|
|
|
1,004,105 |
|
Loss from operations |
|
|
(33,410 |
) |
|
|
(41,450 |
) |
|
|
(76,533 |
) |
|
|
(134,606 |
) |
Other expenses: |
|
|
|
|
|
|
|
|
Interest expense |
|
|
4,605 |
|
|
|
4,414 |
|
|
|
13,496 |
|
|
|
12,991 |
|
Other expenses (income) |
|
|
(131 |
) |
|
|
(48 |
) |
|
|
252 |
|
|
|
(145 |
) |
Loss on extinguishment of debt |
|
|
2,196 |
|
|
|
— |
|
|
|
2,196 |
|
|
|
— |
|
Total other expenses |
|
|
6,670 |
|
|
|
4,366 |
|
|
|
15,944 |
|
|
|
12,846 |
|
Loss before income taxes |
|
|
(40,080 |
) |
|
|
(45,816 |
) |
|
|
(92,477 |
) |
|
|
(147,452 |
) |
Provision for income taxes |
|
|
167 |
|
|
|
— |
|
|
|
167 |
|
|
|
— |
|
Net loss attributable to Alignment Healthcare, Inc. |
|
$ |
(40,247 |
) |
|
$ |
(45,816 |
) |
|
$ |
(92,644 |
) |
|
$ |
(147,452 |
) |
|
|
|
|
|
|
|
|
|
Total weighted-average common shares outstanding - basic and
diluted |
|
|
182,123,363 |
|
|
|
177,828,872 |
|
|
|
180,765,300 |
|
|
|
169,786,542 |
|
Net loss per share - basic and diluted |
|
$ |
(0.22 |
) |
|
$ |
(0.26 |
) |
|
$ |
(0.51 |
) |
|
$ |
(0.87 |
) |
Condensed Consolidated Statements of Cash Flows(in
thousands)(Unaudited) |
|
|
|
Nine Months EndedSeptember 30, |
|
|
|
2022 |
|
|
|
2021 |
|
Operating Activities: |
|
|
|
|
Net loss |
|
$ |
(92,644 |
) |
|
$ |
(147,452 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
Provision for credit loss |
|
|
150 |
|
|
|
74 |
|
Loss on sublease |
|
|
510 |
|
|
|
— |
|
Depreciation and amortization |
|
|
12,735 |
|
|
|
11,884 |
|
Amortization-debt issuance costs and investment discount |
|
|
1,608 |
|
|
|
1,681 |
|
Amortization of payment-in-kind interest |
|
|
2,943 |
|
|
|
3,118 |
|
Equity-based compensation and common stock payments |
|
|
58,833 |
|
|
|
81,786 |
|
Non-cash lease expense |
|
|
2,151 |
|
|
|
2,001 |
|
Loss on extinguishment of debt |
|
|
2,196 |
|
|
|
— |
|
Changes in operating assets and liabilities: |
|
|
|
|
Accounts receivable |
|
|
(29,840 |
) |
|
|
(6,731 |
) |
Prepaid expenses and other current assets |
|
|
(8,742 |
) |
|
|
(11,829 |
) |
Other assets |
|
|
(137 |
) |
|
|
8 |
|
Medical expenses payable |
|
|
45,509 |
|
|
|
15,402 |
|
Accounts payable and accrued expenses |
|
|
2,030 |
|
|
|
(539 |
) |
Deferred premium revenue |
|
|
116,298 |
|
|
|
96 |
|
Accrued compensation |
|
|
7,484 |
|
|
|
4,638 |
|
Lease liabilities |
|
|
(3,126 |
) |
|
|
(2,779 |
) |
Payment-in-kind interest |
|
|
(14,122 |
) |
|
|
— |
|
Net cash provided by (used in) operating activities |
|
|
103,836 |
|
|
|
(48,642 |
) |
Investing Activities: |
|
|
|
|
Purchase of business, net of cash received |
|
|
(2,393 |
) |
|
|
— |
|
Asset acquisition, net of cash received |
|
|
— |
|
|
|
(1,405 |
) |
Purchase of investments |
|
|
(2,825 |
) |
|
|
(2,475 |
) |
Sale of investments |
|
|
2,425 |
|
|
|
1,425 |
|
Acquisition of property and equipment |
|
|
(17,317 |
) |
|
|
(15,409 |
) |
Net cash used in investing activities |
|
|
(20,110 |
) |
|
|
(17,864 |
) |
Financing Activities: |
|
|
|
|
Repurchase of noncontrolling interest |
|
|
(100 |
) |
|
|
15 |
|
Equity repurchase |
|
|
— |
|
|
|
(1,474 |
) |
Issuance of long-term debt |
|
|
165,000 |
|
|
|
— |
|
Debt issuance costs |
|
|
(4,601 |
) |
|
|
— |
|
Repayment of long-term debt |
|
|
(143,179 |
) |
|
|
— |
|
Issuance of common stock |
|
|
— |
|
|
|
390,600 |
|
Common stock issuance costs |
|
|
— |
|
|
|
(29,011 |
) |
Net cash provided by financing activities |
|
|
17,120 |
|
|
|
360,130 |
|
Net increase in cash |
|
|
100,846 |
|
|
|
293,624 |
|
Cash and restricted cash at beginning of period |
|
|
468,350 |
|
|
|
207,811 |
|
Cash and restricted cash at end of period |
|
$ |
569,196 |
|
|
$ |
501,435 |
|
Supplemental disclosure of cash flow
information: |
|
|
|
|
Cash paid for interest |
|
$ |
22,447 |
|
|
$ |
8,193 |
|
Supplemental non-cash investing and financing
activities: |
|
|
|
|
Acquisition of property in accounts payable |
|
$ |
290 |
|
|
$ |
438 |
|
Purchase of business in accounts payable |
|
$ |
375 |
|
|
$ |
— |
|
|
|
|
|
|
The following table provides a reconciliation of cash and
restricted cash reported within the condensed consolidated balance
sheets to the total above:
|
|
September 30,2022 |
|
September 30,2021 |
Cash |
|
$ |
567,446 |
|
|
$ |
500,485 |
|
Restricted cash in other assets |
|
|
1,750 |
|
|
|
950 |
|
Total |
|
$ |
569,196 |
|
|
$ |
501,435 |
|
|
|
|
|
|
Non-GAAP Financial Measures
Certain of these financial measures are considered “non-GAAP”
financial measures within the meaning of Item 10 of Regulation S-K
promulgated by the SEC. We believe that non-GAAP financial measures
provide an additional way of viewing aspects of our operations
that, when viewed with the GAAP results, provide a more complete
understanding of our results of operations and the factors and
trends affecting our business. These non-GAAP financial measures
are also used by our management to evaluate financial results and
to plan and forecast future periods. However, non-GAAP financial
measures should be considered as a supplement to, and not as a
substitute for, or superior to, the corresponding measures
calculated in accordance with GAAP. Non-GAAP financial measures
used by us may differ from the non-GAAP measures used by other
companies, including our competitors. To supplement our
consolidated financial statements presented on a GAAP basis, we
disclose the following non-GAAP measures: Medical Benefits Ratio,
Adjusted EBITDA and Adjusted Gross Profit as these are performance
measures that our management uses to assess our operating
performance. Because these measures facilitate internal comparisons
of our historical operating performance on a more consistent basis,
we use these measures for business planning purposes and in
evaluating acquisition opportunities.
Adjusted EBITDA
Adjusted EBITDA is a non-GAAP financial measure that we define
as net loss before interest expense, income taxes, depreciation and
amortization expense, reorganization and transaction-related
expenses, equity-based compensation expense, loss on sublease and
loss on extinguishment of debt.
Adjusted EBITDA should not be considered in isolation of, or as
an alternative to, measures prepared in accordance with GAAP. There
are a number of limitations related to the use of Adjusted EBITDA
in lieu of net loss, which is the most directly comparable
financial measure calculated in accordance with GAAP.
Our use of the term Adjusted EBITDA may vary from the use of
similar terms by other companies in our industry and accordingly
may not be comparable to similarly titled measures used by other
companies.
Medical Benefits Ratio (MBR)
We calculate our MBR by dividing total medical expenses
excluding depreciation and equity-based compensation by total
revenues in a given period.
Adjusted Gross Profit
Adjusted Gross Profit is a non-GAAP financial measure that we
define as loss from operations before depreciation and
amortization, clinical equity-based compensation expense, and
selling, general, and administrative expenses.
Adjusted Gross Profit should not be considered in isolation of,
or as an alternative to, measures prepared in accordance with GAAP.
There are a number of limitations related to the use of Adjusted
Gross Profit in lieu of loss from operations, which is the most
directly comparable financial measure calculated in accordance with
GAAP.
Our use of the term Adjusted Gross Profit may vary from the use
of similar terms by other companies in our industry and accordingly
may not be comparable to similarly titled measures used by other
companies.
Investor Contact Harrison
Zhuohzhuo@ahcusa.com
Media Contact Maggie HabibmPR, Inc. for
Alignment Healthcarealignment@mpublicrelations.com
Alignment Healthcare (NASDAQ:ALHC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alignment Healthcare (NASDAQ:ALHC)
Historical Stock Chart
From Mar 2023 to Mar 2024